万拉法新与帕罗西汀对难治性抑郁症的疗效

A controlled trial of venlafaxine and paroxetine in treatment-refractory depression

目的:比较万拉法新与帕罗西汀对难治性抑郁症的疗效及不良反应。 方法:67例患者符合中国精神疾病分类方案与诊断标准第2版修订本抑郁症诊断标准,经两种抗抑郁药正规治疗无效,随机分为万拉法新与帕罗西汀两组,治疗6周。 结果:万拉法新对难治性抑郁症的疗效明显优于帕罗西汀,显效率达64.7％;且起效迅速,不良反应与帕罗西汀相仿,均较轻微。 结论:万拉法新对难治性抑郁症有较好的疗效,起效快,不良反应轻微。

Objective: To compare the efficacy and side effects between venlafaxine and paroxetine. Method .-Sixty-seven inpatients with refractory depression were randomly assigned to receive venlafaxine or paroxetine for six weeks. Results: Venlafaxine was superior in efficacy to paroxetine. The response rate was 64.7 % for venlafaxine and 42.2% for paroxetine.Overall tolerance was similar for the two drugs. Conclusion: Venlafaxine is an effective drug for refractory depression, with rapid onset of action and good tolerance.